The Role of the PI3K Signaling Pathway in CD4+ T Cell Differentiation and Function by Jonathan M. Han et al.
REVIEW ARTICLE
published: 13 August 2012
doi: 10.3389/fimmu.2012.00245
The role of the PI3K signaling pathway in CD4+T cell
differentiation and function
Jonathan M. Han, Scott J. Patterson and Megan K. Levings*
Department of Surgery, Child and Family Research Institute, The University of British Columbia, Vancouver, BC, Canada
Edited by:
Michael R. Gold, The University of
British Columbia, Canada
Reviewed by:
Bruce David Mazer, McGill University
Health Center – Montreal Children’s
Hospital, Canada
Klaus Okkenhaug, Babraham
Institute, UK
*Correspondence:
Megan K. Levings, Department of
Surgery, Child and Family Research
Institute, The University of British
Columbia, A4-186, 950West 28th
Avenue, Vancouver, BC, Canada V5Z
4H4.
e-mail: mlevings@mail.ubc.ca
The relative activity of regulatory versus conventional CD4+ T cells ultimately maintains
the delicate balance between immune tolerance and inflammation. At the molecular level,
the activity of phosphatidylinositol 3-kinase (PI3K) and its downstream positive and nega-
tive regulators has a major role in controlling the balance between immune regulation and
activation of different subsets of effector CD4+ T cells. In contrast to effectorT cells which
require activation of the PI3K to differentiate and mediate their effector function, regulatory
T cells rely on minimal activation of this pathway to develop and maintain their characteristic
phenotype, function, and metabolic state. In this review, we discuss the role of the PI3K
signaling pathway in CD4+T cell differentiation and function, and focus on how modulation
of this pathway inT cells can alter the outcome of an immune response, ultimately tipping
the balance between tolerance and inflammation.
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INTRODUCTION
Immune tolerance is a state where the immune system is unable to
mount an inflammatory response toward a particular substance,
thus ensuring inappropriate immunity to self or non-harmful for-
eign antigens is kept in check. Tolerance is controlled by two
major mechanisms: central tolerance in the thymus that results
in deletion of the majority of self-reactive T cells; and peripheral
tolerance, which is mediated by a variety of pathways and processes
including anergy, deletion, and immune regulation. Since the
breakdown of immune tolerance can lead to a variety of dis-
eases such as type 1 diabetes, allergy, and inflammatory bowel
disease, there is intense research into the cellular and molecular
mechanisms which control this process.
In the past 10 years, immune regulation mediated by specific
types of T cells has emerged as one of the most important mech-
anisms of peripheral tolerance. Specifically, specialized T cells
known as regulatory T cells (or Tregs) emerge in the thymus and
periphery and are dedicated to turning off immune responses
(Sakaguchi et al., 2010; Rudensky,2011). There are several different
types Tregs, including specialized subsets of CD4+, CD8+, dou-
ble negative CD3+CD4−CD8−, γδ T cells, and NKT cells (Allan
et al., 2008). While it is likely that these different types of Tregs
work together in a network to maintain immune homeostasis, the
majority of current research is focused on CD4+ Tregs since these
cells are known to mediate dominant, long lasting, and transferable
tolerance in experimental models (McMurchy et al., 2011).
Recently, the phosphatidylinositol 3-kinase (PI3K) signaling
pathway has emerged as a key molecular regulator of immune
tolerance. Modulating this pathway using drugs or genetic manip-
ulation has revealed the importance of PI3K and its downstream
signaling components in regulating Treg development and func-
tion, maintaining the balance between Tregs and conventional
CD4+ T cells, and controlling the distinct metabolic requirements
of different CD4+ T cell subsets. In this review, we will discuss the
current state of knowledge on how PI3K, its downstream signal-
ing pathways, and its negative regulators, control the development
and function of CD4+ T cells, with a specific focus on Tregs and
immune tolerance.
OVERVIEW OF THE PI3K SIGNALING PATHWAY IN T CELLS
Although there are four classes of PI3K, only class IA and class
IB PI3K have been comprehensively studied in T cells. Most
research is focused on the p110δ class IA catalytic subunit and
the p110γ class IB catalytic subunit since these proteins are
preferentially expressed in leukocytes (Huang and Sauer, 2010).
Class IA PI3Ks are activated by receptor tyrosine kinases such
as cytokine receptors and the T cell receptor (TCR), while class
IB PI3Ks are primarily activated by G protein-coupled recep-
tors (GPCRs) such as chemokine receptors. Class I PI3K phos-
phorylates phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2] to
form phosphatidylinositol-3,4,5-triphosphate [PIP3] on the inner
membrane of the cell, thus initiating the recruitment and activa-
tion of downstream signaling components such as PDK1 and its
substrate AKT (Figure 1). AKT activation requires phosphory-
lation by PDK1 at Thr308, and for full activation, and a subse-
quent second phosphorylation by mTORC2 or DNA-PK at Ser473
(Bhaskar and Hay, 2007; Fayard et al., 2010). In the nucleus, acti-
vated AKT phosphorylates and consequently promotes nuclear
exclusion and inhibition of FOXO transcription factors, which
consist of four family members (FOXO1, FOXO3a, FOXO4, and
FOXO6) (Hay, 2011; Ouyang and Li, 2011). Another consequence
of AKT kinase activity is activation of mTORC1 via Rheb-GTPase
(Huang and Manning, 2009). Several phosphatases negatively reg-
ulate the PI3K pathway, including the lipid phosphatases PTEN
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FIGURE 1 |The role of PI3K/AKT signaling pathway inTregs. Arrow
indicates activating phosphorylation; line with a perpendicular line at the end
indicates inhibitory phosphorylation; line with a circle at the end indicates
dephosphorylation; dashed line indicates resulting outcome of signaling.
Green represents components of the PI3K/AKT pathway which have been
shown to be beneficial for Treg function and/or development. On the contrary,
red indicates molecules with activity thought to be inhibitory for Treg function
and/or development.
and SHIP that dephosphorylate PIP3 (Harris et al., 2008), and the
protein phosphatase PHLPP that dephosphorylates AKT (Brog-
nard and Newton, 2008). The generation of PIP3 by PI3K also
plays a role in the recruitment and activation of other signaling
proteins in T cells such as Tec family of kinases (Huang and Sauer,
2010), which have not been extensively studied in Tregs and will
not be discussed.
THE ROLE OF THE PI3K PATHWAY IN Treg DEVELOPMENT
AND FUNCTION
The best-defined type of Tregs is CD4+ and characterized by high
and constitutive expression of a transcription factor known as
FOXP3. Genetic mutations in FOXP3, which cause defects in the
development and function of Tregs, result in a severe and often
fatal multi-organ autoimmune disease called Scurfy in mice and
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Immunodysregulation, Polyendocrinopathy and Enteropathy, X-
linked (IPEX) in humans, illustrating the essential role of Tregs
in immune tolerance (Bacchetta et al., 2006; Gambineri et al.,
2008; McMurchy et al., 2009, 2010). FOXP3-expressing Tregs can
be divided into two distinct subsets: natural Tregs that develop
in the thymus via central tolerance mechanisms, and peripher-
ally induced Tregs, which differentiate from naïve T cells when
self or non-self antigen is encountered in the periphery under
tolerogenic conditions. Tregs utilize a variety of mechanisms to
suppress conventional T cells as well as other immune cells such
as macrophages, dendritic cells, and NK cells (Ghiringhelli et al.,
2005; Tiemessen et al., 2007; Onishi et al., 2008). Some of the
mechanisms used by Tregs to suppress immunity include expres-
sion of surface inhibitory molecules such as CTLA-4 and CD39,
and secretion of anti-inflammatory cytokines such as TGF-β,
IL-10, and IL-35 (Vignali et al., 2008; Sakaguchi et al., 2009).
This section of the review will discuss the role of PI3K sig-
naling in the development and function of thymically derived
natural Tregs.
KINASES IN THE PI3K SIGNALING PATHWAY THAT AFFECT
NATURAL Tregs
In order to define the function of PI3K in natural Tregs, most stud-
ies have focused on the p110δ catalytic subunit and used mice
with a kinase-inactive knocked-in form of p110δ (p110δD910A).
The role of p110γ in Treg development and function has not been
clearly defined, although chemical inhibition of p110γ can induce
peripheral Treg differentiation in vivo (Dutra et al., 2011; discussed
further below). p110δD910A mice have an increased proportion of
Tregs in the thymus, but reduced in the spleen and lymph nodes
(Patton et al., 2006). In addition, these Tregs are less suppressive and
cannot produce the anti-inflammatory cytokine IL-10, as a result,
p110δD910A mice develop spontaneous colitis (Patton et al., 2006)
and enhanced resistance to Leishmania major infections (Liu et al.,
2009). These data suggest that p110δ activity is not required for
the development of Tregs, but rather for their function and main-
tenance in the periphery. The effect of p110δ inactivation is not
specific to Tregs since CD4+ T cells in these mice are less prolifera-
tive and have reduced IL-2, IL-4, and IFN-γ production, suggesting
a general impairment in both Th1 and Th2 responses. Despite
the defects in Tregs and resistance to primary L. major infections,
p110δD910A mice are more susceptible to secondary L. major infec-
tions, due to insufficient generation of Th1-polarized memory
cells (Liu and Uzonna, 2010). A subsequent study reported that
the p110δD910A mice have a specific reduction in Tregs expressing
high levels of CD38, a marker thought to define a highly suppres-
sive population of Tregs (Patton et al., 2011). Together these studies
suggest that reduced activity of the p110δ form of PI3K is detri-
mental to the effector and suppressive functions of Th cells and
Tregs, respectively. On the other hand, as discussed below, there is
also evidence that excessive activity of PI3K signaling is inhibitory
to Tregs. Thus maintaining the correct threshold of PI3K activity
is critical for the normal function of these cells.
Although there is clearly a requirement for a certain level of
PI3K activity to maintain Tregs in the periphery, Tregs have a signifi-
cantly diminished ability to activate the PI3K pathway downstream
of the TCR (Crellin et al., 2007). Diminished signaling is evident
not only in terms of reduced AKT phosphorylation, but also at the
level of downstream effectors including reduced phosphorylation
of p70 S6K and of FOXO1 and FOXO3a at Ser256 (Crellin et al.,
2007). Notably, diminished AKT phosphorylation is most evident
at Ser473, with normal phosphorylation of Thr308, suggesting
that activation of PDK1 is normal. This low activity of AKT is
essential for the normal function of Tregs since over-expression of
an inducibly active form of AKT abolishes their suppressive func-
tion (Crellin et al., 2007). Mechanistically, it remains unknown
why high activity of AKT block suppression in mature Tregs since
it does not result in a change in expression of FOXP3, IL-2,
CTLA-4, or granzyme B; although trans-differentiation into effec-
tor cells may play a role since enforced AKT activation causes
Tregs to produce high amounts of IFN-γ and IL-4 (Crellin et al.,
2007). Constitutive activation of AKT also represses thymic Treg
development (Haxhinasto et al., 2008) suggesting that high PI3K
activity is detrimental to both the development and function of
natural Tregs.
Many of the studies investigating the role of mTOR in Tregs
have relied on the use of rapamycin (also known as sirolimus),
which selectively inhibits mTORC1 at low doses but can also
inhibit mTORC2 at higher doses (Delgoffe et al., 2011). Unlike
conventional T cells, Tregs are resistant to rapamycin-induced
apoptosis (Strauss et al., 2009) and hence this drug can selectively
block pro-inflammatory T cells while preserving Tregs (Battaglia
et al., 2006; Qu et al., 2007; Lu et al., 2010; Zuber et al., 2011)
and their suppressive function (Singh et al., 2012). These data
support the conclusion that activation of Tregs does not require
strong activity of the PI3K pathway. Because of this distinct mol-
ecular property, the PI3K signaling pathway represents an ideal
target for pharmacological immunomodulation. Indeed in mouse
models, rapamycin induces Treg-mediated tolerance and protects
mice against graft rejection (Eng et al., 1991; Zheng et al., 2003;
Gagliani et al., 2011), and acute graft versus host disease (Shin et al.,
2011). Clinically, use of rapamycin is associated with increased fre-
quency of Tregs following lung transplantation (Lange et al., 2010),
and increased suppressive activity of Tregs in islet transplantation
(Monti et al., 2008). On the other hand, some clinical data show
an association between rapamycin and an increased incidence of
acute rejection (Zuber et al., 2011), possibly due to the paral-
lel ability of rapamycin to expand memory T cells and enhance
cytokine production by antigen presenting cells (Saemann et al.,
2009; Li et al., 2011). Moreover, rapamycin has many deleteri-
ous side effects such as inhibition of islet survival and function
(Tanemura et al., 2012), and induction of glucose intolerance and
hyperlipidemia (Morrisett et al., 2002; Houde et al., 2010). Thus
the favorable effects of rapamycin on immune tolerance must be
weighed against the adverse effects of this drug.
THE ROLE FOXO PROTEINS IN NATURAL Tregs
Since natural Tregs have diminished AKT activity it was predicted
that continued activity of FOXO may be important for their devel-
opment and function. Indeed, when both FOXO1 and FOXO3a are
deleted specifically in T cells, there is reduced development and
function of natural Tregs, resulting in a multi-organ inflammatory
disorder (Ouyang et al., 2010). By corollary, enforced FOXO activ-
ity results in impaired proliferation and survival of conventional T
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cells (Fabre et al., 2005), illustrating that the relative activity of this
transcription factor is key for maintaining the balance between tol-
erance and immunity. Mechanistically, FOXO1 and FOXO3a are
likely required for Treg development and function because they
bind and transactivate the FOXP3 promoter, the essential lineage
defining transcription factor for Tregs (Ouyang et al., 2010). Inter-
estingly, the FOXO-deficient Tregs that do develop produce large
amounts of IFN-γ and IL-17, and only weakly express FOXP3,
CD25, and CTLA-4 (Ouyang et al., 2010), suggesting that beyond
developmental control, FOXO (and the PI3K pathway) can also
control the stability of the Treg lineage. Further investigation is
required to study how different environments affect the activity of
the PI3K in Tregs and hence their stability and function.
THE ROLE OF PHOSPHATASES IN THE PI3K PATHWAY IN NATURAL Tregs
One reason that could explain why natural Tregs have diminished
activity of the PI3K pathway could be that they have high activ-
ity of one or more of the phosphatases that negatively regulate
the pathway. SHIP is a lipid phosphatase that dephosphorylates
PIP3 into phosphatidylinositol-3,4-bisphosphate [PI(3,4)P2]. It
is now clear that SHIP does not terminate PI3K signaling, but
rather modulates it as some proteins, such as TAPP1 and TAPP2,
are preferentially recruited to PI(3,4)P2 and initiate distinct sig-
naling pathways (Zhang et al., 2009). SHIP-1−/− mice have an
elevated percentage of natural Tregs which are suppressive in vitro
and in vivo (Locke et al., 2009), but this apparent enhanced Treg
development is likely due to a T cell extrinsic effect of SHIP, since
mice with a SHIP-1 deletion only in CD4+ T cells do not display
this phenotype (Tarasenko et al., 2007). Moreover, Tregs do not
express high levels of SHIP-1 (our unpublished data), supporting
the overall conclusion that there is no intrinsic role for SHIP-1 in
Treg development or function.
PTEN is another lipid phosphatase that directly counteracts
and terminates the activity of PI3K. Tregs from mice with a CD4+
T cell specific PTEN deficiency develop and function normally, but
they are hyper-proliferative in response to stimulation with IL-2,
even in the absence of TCR activation (Walsh et al., 2006; dis-
cussed further below). PTEN may thus have an important role in
maintaining peripheral Treg expansion by regulating IL-2-induced
PI3K signaling in the context of continual expression of the high
affinity IL-2R.
Since the reduction of AKT activity in Tregs is consistently found
at the level of phosphorylation of Ser473 but not Thr308, when
a novel Ser473-specific protein phosphatase, known as PHLPP
(Gao et al., 2005; Brognard et al., 2007; Liu et al., 2011), was
identified in 2005 it was an attractive candidate for a negative
regulator of the PI3K pathway in Tregs. There are two genes in
this family: PHLLP1 and PHLPP2. PHLPP1 is expressed as two
isoforms, resulting in a total of three isozymes that differentially
control the phosphorylation of the three different isoforms of
AKT. We found that both mouse and human natural Tregs express
significantly more PHLPP1 mRNA compared to conventional T
cells, and moreover, that expression of the protein was critical for
their function (Patterson et al., 2011). Although natural Tregs in
PHLPP1−/− mice developed normally, they were dysfunctional
both in vitro and in vivo. In addition, PHLPP1−/− Tregs had com-
pletely restored phosphorylation of AKT at Ser473, suggesting that
high expression of PHLPP1 in Tregs is the molecular mechanism
controlling low activity of the PI3K pathway in these cells. More
recent work indicates that PHLPP can also dephosphorylate con-
ventional PKCs, and it will be critical to determine whether Tregs
also have altered activity of this pathway and how this may impinge
on their function (Gao et al., 2005; Brognard et al., 2007; Liu et al.,
2011).
REGULATION OF PI3K SIGNALING PATHWAY BY
CO-STIMULATORY AND CO-INHIBITORY MOLECULES IN Tregs
Much of the biochemistry of the PI3K pathway in Tregs has been
studied in the context of TCR activation, but it is important con-
sider that this pathway is activated by many different receptors
and that the net result will be the integrated signaling that is
stimulated by all the factors in the local environment (Figure 2).
Co-stimulatory molecules are essential for full T cell activation
and have long been known to modulate the level of PI3K signal-
ing induced by the TCR. Indeed CD28-stimulated activation of
AKT is a prototypic signaling mechanism that is required for full
activation of conventional T cells.
CD28 co-stimulation is an integral part of the development
(Tai et al., 2005) and function of Tregs (Golovina et al., 2008).
Somewhat unexpectedly, we found that even co-stimulation via
CD28 in combination with the TCR was not sufficient to restore
AKT phosphorylation in Tregs, illustrating the strength of nega-
tive regulation of this pathway in these cells (Crellin et al., 2007;
Patterson et al., 2011). In addition to PI3K, many of the effects of
CD28 on thymic Treg development are mediated via the NF-κB
FIGURE 2 | Intracellular “tug-of-war” determinesT cell fate. Green
arrow indicates activation of PI3K signaling; red arrow indicates inhibition of
PI3K signaling. The strength of PI3K signaling is influenced by opposing
activation and inhibitory signals that are integrated from extracellular stimuli
such as co-stimulation, co-inhibition, and cytokines/adipokines. Ultimately,
the outcome of this “tug-of-war” determines whether a T cell becomes a
Treg to mediate tolerance, or inflammatory Th subsets to mediate immunity.
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pathway, and specifically the c-Rel family member (Deenick et al.,
2010; Vang et al., 2010). The role of CD28-mediated activation of
the NF-κB pathways in fully developed Tregs remains to be inves-
tigated. In conventional T cells, CD28-mediated activation of the
PI3K pathway is necessary for the induction of anti-apoptotic pro-
teins (Okkenhaug et al., 2001), and the induction of glucose uptake
via surface expression of GLUT1 glucose transporter (Frauwirth
et al., 2002; Jacobs et al., 2008), suggesting that Tregs, which have
diminished CD28-induced PI3K signaling, may use distinct sig-
naling mechanisms to survive and fulfill their metabolic demands
(discussed further below). There is evidence that excessive CD28
signaling inhibits immune tolerance, for example, CD28 blockade
promotes Tregs in organ transplantation (Poirier et al., 2010), but
whether the underlying mechanism of CD28 blockade involves
modulation of PI3K activity remains to be investigated.
In addition to CD28, the function and biochemical activity of
other co-stimulatory and co-inhibitory pathways, such as OX40,
CLTA-4, ICOS, and PD-1, have recently been studied in Tregs.
Whereas CLTA-4 and PD-1 suppress PI3K activation, OX40L, and
ICOS strongly activate this pathway, leading to the prediction that
ligation of the former molecules should promote Treg develop-
ment and function whereas the latter should block these processes.
Curiously, Tregs express high levels of all these molecules, suggest-
ing they are poised to have their PI3K pathway turned on or off in
response to different environments.
OX40 is expressed on Tregs in the absence of immune activation
(Sakaguchi, 2004), and, as in activated effector T cells (So et al.,
2011), OX40 engagement in Tregs activates AKT (Xiao et al., 2012).
Studies to investigate whether OX40 engagement positively or neg-
atively affects Tregs have produced conflicting data. Some studies
suggest that Tregs lacking OX40 lose suppressive function in vivo
(Griseri et al., 2010), while others report that OX40 activation
interferes with Treg function (Vu et al., 2007; Piconese et al., 2008).
A recent study suggests that the effect of OX40 on Tregs may depend
on the abundance of IL-2 (Xiao et al., 2012), which activates STAT5
but not the PI3K pathway in Tregs (Bensinger et al., 2004). Specifi-
cally, OX40 stimulation renders Tregs non-suppressive unless IL-2
is abundant. Thus an optimal balance between the PI3K pathway
activated by OX40 and the STAT5 pathway activated by IL-2 may
be important for regulating both Treg proliferation and function.
ICOS expression defines a subset of effector Tregs that are highly
suppressive and selectively produce high amounts of IL-10 (Ito
et al., 2008) and IL-35 (Whitehead et al., 2012), a phenotype which
is likely related to the fact that ICOS expression is induced upon
antigen specific activation of Tregs in vivo (Vocanson et al., 2010).
ICOS ligation potently stimulates PI3K activation in conventional
T cells (Fos et al., 2008; Simpson et al., 2010), but it is not known
whether ICOS stimulation can similarly induce strong PI3K signal-
ing in Tregs. Thus it remains to be investigated whether the reduced
numbers of peripheral Tregs in the absence of ICOS (Burmeister
et al., 2008) is related to activation of the PI3K pathway in Tregs.
In contrast to CD28 and other positive co-stimulatory recep-
tors, co-inhibitory receptors such as CTLA-4 and PD-1 typically
inhibit TCR-induced PI3K signaling (Parry et al., 2005), and
both proteins are highly expressed in Tregs (Takahashi et al.,
2000; Raimondi et al., 2006). Although CTLA-4 engagement does
not inhibit PI3K directly, it is thought that CTLA-4 utilizes the
serine/threonine protein phosphatase PP2A to dephosphorylate
and inactivate AKT in CD4+ T cells (Parry et al., 2005). However,
others claim that the inhibitory property of CTLA-4 on T cells
is separate from the PI3K/AKT pathway, and that CTLA-4 can
signal and activate the PI3K/AKT pathway to promote T cell sur-
vival (Schneider et al., 2008). A recent study supports the concept
that Treg suppression mediated via CTLA-4 inhibits intracellular
signaling in Tregs (Tai et al., 2012).
PD-1 stimulation disrupts the accumulation of PIP3 in CD4+
T cells by recruiting SHP-2, which subsequently blocks the recruit-
ment and activation of PI3K (Parry et al., 2005; Saunders et al.,
2005). PD-L1 and PD-L2 expression on antigen presenting cells,
such as tolerogenic dendritic cells, is crucial for efficient differen-
tiation of induced Tregs from conventional T cells (Francisco et al.,
2009). Mechanistically this role in Treg differentiation is mediated
by PD-1-induced down-regulation of AKT and mTOR activity
and parallel up-regulation of PTEN (Wang et al., 2007; Francisco
et al., 2009; Maldonado and von Andrian, 2010).
Clearly, the effects of these co-receptors on conventional T cells
versus Tregs, and the consequent balance of PI3K signaling are cru-
cial in dictating the state of immune tolerance. As biological agents
blocking, or in some cases stimulating, the function of these mol-
ecules enter clinical trials (Vincenti, 2007; Weber, 2007; Ford and
Larsen, 2009), further research is needed to explore the functional
consequences on the activity of the PI3K pathway and the resulting
biological effects of Tregs versus conventional T cells.
REGULATION OF PI3K SIGNALING PATHWAY BY CYTOKINES
IN Tregs
Cytokines have a major role in directing and sustaining T cell
responses, and these molecules also directly regulate the PI3K
pathway. Although mature, fully developed Tregs respond to many
cytokines, to date only the biochemical effects of IL-2 and leptin,
an adipo-cytokine, have been intensively studied in these cells.
IL-2R signaling is essential for Treg development and survival
(Almeida et al., 2002), but the signaling pathway triggered by the
receptor is different compared to conventional T cells. Although
STAT5 signaling downstream of IL-2R remains intact, as for the
TCR,IL-2-stimulated PI3K signaling is selectively inhibited in Tregs
(Bensinger et al., 2004). This defect in PI3K signaling downstream
of the IL-2R has been attributed to the expression of PTEN as
PTEN−/− Tregs are hyper-proliferative to IL-2 stimulation, even
in the absence of TCR stimulation. These data suggest that PTEN
is responsible for keeping IL-2-stimulated proliferation of Tregs
in check despite their continuous expression of the high affinity
IL-2R (Walsh et al., 2006). It would be of interest study whether
Tregs also have defective PI3K pathway activation upon stimulation
with other common gamma chain cytokines such as IL-7, which
has recently been shown to be required for Treg maturation and
homeostasis (Di Caro et al., 2011; Kim et al., 2012), and IL-15,
which, much like IL-2, also stimulates expansion of Tregs ex vivo
(Levings et al., 2002). In addition, since polarizing cytokines such
as IL-6 and IL-12 have been suggested to affect the stability of the
Treg lineage, their downstream receptor signaling pathways should
be explored in Tregs. Finally the neuropeptide hormone vasoactive
intestinal peptide inhibits PI3K signaling in T cells and promotes
Treg differentiation, indicating that the effects of cytokines which
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are not normally considered part of the immune response should
also be considered (Anderson and Gonzalez-Rey, 2010).
Recent studies have shown that adipocyte-derived cytokines,
or adipokines, modulate T cell responses via the PI3K signal-
ing pathway, and that this process affects the function of Tregs.
Most research has focused on leptin, an adipokine induced by
food intake and glucose metabolism to control appetite. Specif-
ically, leptin is thought to negatively regulate Treg proliferation
by activating mTOR. In parallel, leptin promotes T cell medi-
ated inflammation by enhancing Th1 and Th17 responses, and
the survival of autoreactive T cells (Galgani et al., 2010; Matarese
et al., 2010). Surprisingly, Tregs themselves secrete leptin, and the
autocrine effects of this adipokine are thought to induce activation
of mTOR (De Rosa et al., 2007; Procaccini et al., 2010). Leptin-
induced mTOR activity in Tregs causes them to be anergic in vitro,
and by corollary leptin blockade restores Treg activation and pro-
liferation. Thus oscillatory changes in mTOR activity, controlled
partially by leptin, could be necessary for the ability of Tregs to
vigorously proliferate in vivo (Procaccini et al., 2010).
In support of a major role for adipokines in controlling immune
tolerance, leptin receptor deficient Tregs maintain their suppressive
function but have an increased proliferative potential (De Rosa
et al., 2007). Similarly, leptin deficient (ob/ob) mice have increased
numbers of peripheral Tregs and are resistant to experimental
autoimmune encephalomyelitis (Matarese et al., 2001). These data
contrast to a recent observation that the inflamed adipose tis-
sue in ob/ob mice has a decreased proportion of adipose-resident
Tregs (Feuerer et al., 2009; Winer et al., 2009), suggesting there
may be tissue specific effects of adipokines. Overall, the data from
the above studies are consistent with the widely accepted notion
that chronic activation of mTOR inhibits Tregs. With growing evi-
dence that Tregs have a role in metabolic disorders, it is important
to understand how signals from metabolic and classical immune
stimuli are integrated.
Tregs MODULATE PI3K SIGNALING ACTIVITY IN TARGET
CELLS AS PART OF THEIR SUPPRESSIVE MECHANISM
Since damping of PI3K signaling is strongly associated with
depressed T cell activation, it can be hypothesized that Tregs may
modulate this pathway in order to suppress their targets. In sup-
port of this concept, effector T cells with hyperactive PI3K/AKT
activity become resistant to suppression by Tregs (King et al., 2006;
Ben Ahmed et al., 2009) and Tregs attenuate the activation of AKT
in CD8+ T cells (Kojima et al., 2005). Via CTLA-4 expression,
Tregs also compete with CD28 expressed on conventional T cells
for access to CD80/86 on antigen presenting cells (Greenwald et al.,
2005), and can physically remove these co-stimulatory ligands
from APCs (Qureshi et al., 2011). As a result, Tregs can indirectly
limit CD28-induced PI3K activation in their targets. Furthermore,
by producing high levels of IL-10, Tregs can cause phosphorylation
and activation of SHP-1, a tyrosine phosphatase that inhibits the
recruitment of PI3K, thus hindering T cell activation (Taylor et al.,
2007). In addition, IL-10 can stabilize the expression of SHIP-1 via
blocking miR-155, a micro RNA that targets SHIP-1 for degrada-
tion, in macrophages (McCoy et al., 2010). Lastly, Tregs also express
PD-L1 (Francisco et al., 2010), which upon ligation to PD-1 on
effector T cells, can inhibit PI3K activity via induction of SHP-2
(Parry et al., 2005). It can be speculated that the ability of Tregs
to limit PI3K signal strength in conventional T cells would cre-
ate a condition favorable for peripheral Treg differentiation, hence
contributing to infectious tolerance (Kendal et al., 2011).
THE ROLE OF PI3K SIGNALING PATHWAY IN PERIPHERAL
CD4+ T CELL POLARIZATION
Depending on the context of stimulation upon activation, naive T
cells differentiate into distinct subsets, which are characterized by
lineage defining transcription factors and profiles of cytokine pro-
duction. One arm of T cell differentiation includes the peripheral
development of induced Tregs which are important for tolerance
to harmless commensals and prevention of over-active immune
responses against pathogens (Chen and Konkel, 2010). The other
arms include Th1, Th2, and Th17 cells, as well as a variety of other
newly described Th cell subsets (Zhu and Paul, 2010). Since the
relative activity of PI3K plays a key role in regulating Th cell polar-
ization, this in an additional way that the activity of this pathway
modulates the balance between tolerance and immunity.
KINASES IN THE PI3K SIGNALING PATHWAYWHICH AFFECT CD4+ T
CELL DIFFERENTIATION
Studies involving inhibition of PI3K activity have revealed separate
roles for p110δ and p110γ in peripheral CD4+ Th polarization.
Specific inhibition of p110δ using IC87114 blocks the release of
multiple cytokines by human T cells, including IFN-γ, TNF-α, IL-
5, and IL-17 (Soond et al., 2010). Similarly, genetic manipulations
to inactivate p110δ results in reduced production of IL-4, IL-17,
IFN-γ, and IL-10 by different T cell subsets (Okkenhaug et al.,
2006; Patton et al., 2006), hence disrupting Th1, Th2, Th17, and
Treg associated cytokines. These data suggest that p110δ plays an
indispensable role in multiple CD4+ Th cell subsets. On the other
hand, p110γ does not seem to have a major role in T cell acti-
vation (Gruen et al., 2010), and its expression is dispensable for
Th1 and Th17 differentiation (Berod et al., 2011). Interestingly,
blockade of p110γ by administration of its inhibitor AS605240 in
mice can induce Tregs in vivo and consequently ameliorate colitis
(Dutra et al., 2011). Together, these studies suggest that inhibition
of p110δ may be beneficial for treating inflammatory disorders
where cytokines are over-produced; however, since p110δ activ-
ity is essential for Tregs, immune tolerance would likely not be
achieved in parallel. On the contrary, inhibition of p110γ may be
beneficial in achieving long lasting tolerance by inducing Tregs, but
may be relatively ineffective at controlling ongoing Th1 and Th17
responses.
There are contradicting results regarding the role of AKT in
peripheral differentiation of induced Tregs. Constitutive AKT acti-
vation impairs FOXP3 induction during in vitro TGF-β driven
Treg differentiation (Haxhinasto et al., 2008), suggesting a require-
ment for reduced AKT activity in peripheral Treg differentiation
similar to that in natural Treg development. In contrast, another
study found that in the absence of CD28 co-stimulation, AKT
transgenic CD4+ T cells have an enhanced capacity to differenti-
ate into Tregs (Pierau et al., 2009). In addition, CD28 signaling is
required for the survival of induced Tregs (Liu et al., 2006), sug-
gesting that in the former study constitutive AKT activity may
substitute for the requirement of co-stimulation. On the other
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hand, CD28 co-stimulation may influence peripheral Treg differ-
entiation via other signaling pathways such as activation of c-Rel,
which has been shown to play a role in thymic Treg development
(Deenick et al., 2010; Vang et al., 2010). Since AKT is central to
various cellular processes including cell survival pathways, it is
possible that peripheral Treg development requires some level of
AKT activation, provided by CD28 co-stimulation, but which must
then be maintained at a relatively low level for the cells to stabilize
FOXP3 expression and retain suppressive function.
The activity of mTOR, which forms part of the mTORC1 or
mTORC2 kinase complexes when bound to the scaffold proteins
Raptor or Rictor, respectively (Laplante and Sabatini, 2009), tightly
regulates Th cell differentiation. Deletion of Rictor, which disrupts
mTORC2, impairs both Th1 and Th2 differentiation (Lee et al.,
2010). The effect on Th1 cells is due to the fact that expression of
TBET, the defining transcription factor for Th1 cells, is repressed
by FOXO1. In the absence of mTORC2,AKT activity is diminished,
FOXO1 is not repressed and hence TBET expression is prevented.
In contrast, the effect of mTORC2 deletion on Th2 cells does not
seem to be related to AKT or FOXO1. On the contrary, another
study reported that while Rictor−/− T cells fail to differentiate
into Th2 cells, they can still differentiate into Th1 cells (Delgoffe
et al., 2011). Rheb−/− T cells, which lack the GTPase required for
mTORC1 activity, cannot successfully differentiate into Th1 or
Th17 cells, but maintain the capacity for Th2 differentiation.
Both mTORC1 and mTORC2 antagonize the peripheral differ-
entiation of Tregs. While Rictor−/− T cells have enhanced TGF-β
mediated Treg differentiation (Lee et al., 2010), mTOR-deficient T
cells that lack both mTORC1 and mTORC2 readily differentiate
into Tregs in the absence of TGF-β (Delgoffe et al., 2011). Further-
more, the lack of both mTOR complexes renders T cells unable to
skew into Th1, Th2, and Th17 cells (Delgoffe et al., 2009). In agree-
ment with these genetic data, inhibition of mTOR by rapamycin,
promotes FOXP3 expression and Treg generation (Kopf et al., 2007;
Kang et al., 2008).
In summary, studies of mTOR have shown that mTORC1
is required for differentiation of Th1 and Th17 cells, but not
Th2 cells. mTORC2 is most important for Th2 differentiation,
but also plays a role in Th1 differentiation, and both mTORC1
and mTORC2 negatively regulate the peripheral differentiation of
Tregs. Hence differential targeting of mTORC1 versus mTORC2
could be used to alter the balance of effector T cell subsets and
promote immune suppression.
THE ROLE OF FOXO PROTEINS IN CD4+ T CELL DIFFERENTIATION
As discussed above, one of the main ways that the PI3K pathway
blocks the differentiation of Tregs is via inactivation of FOXO1 and
FOXO3a, transcription factors which are necessary for induction
of FOXP3 expression (Ouyang et al., 2010). In agreement, ablation
of Cbl-b, which results in FOXO3a inactivation in a PI3K depen-
dent manner, also impairs Treg differentiation in vitro and in vivo
(Harada et al., 2010). Impaired Treg differentiation can be rescued
by over-expression of FOXO3a, and mice lacking FOXO3a have
increased Th1 and Th2 cells (Lin et al., 2004). Together these data
indicate that regulation of FOXO activity is the critical arm of the
PI3K pathway controlling the balance between immune tolerance
and inflammation.
PHOSPHATASES IN THE PI3K SIGNALING PATHWAY THAT AFFECT CD4+
T CELL DIFFERENTIATION
As negative regulators of the PI3K pathway, phosphatases such as
SHIP also have crucial roles in Th cell differentiation. Systemic
SHIP-1 deletion results in reduced numbers of Th17 but not Th1
cells. Furthermore, when naive T cells from SHIP-1−/− mice are
transferred into immunodeficient mice, they are less able to induce
colitis, possibly due to their reduced IL-17 production and parallel
tendency to differentiate into induced Tregs (Locke et al., 2009). In
studies of mice with a T cell specific SHIP-1 deletion, SHIP-1−/− T
cells themselves have a reduced capacity to differentiate into Th2
cells (Tarasenko et al., 2007). Furthermore, SHIP-1−/− Th2 cells
produce less IL-4, suggesting that SHIP-1 is an intrinsic positive
regulator of Th2 responses (Tarasenko et al., 2007; Roongapinun
et al., 2010). Interpretations on effects of the PI3K pathway from
these studies of SHIP−/− T cells have to be taken with caution as
SHIP does not simply reverse PI3K activity, but rather modulates
the downstream signaling effects through a modified lipid second
messenger PI(3,4)P2, which can also act by recruiting adaptor
proteins (Zhang et al., 2009).
T cell deficiency of PTEN results in enhanced AKT activa-
tion and resistance to TGF-β driven differentiation of induced
Tregs (Sauer et al., 2008). On the other hand, T cell specific PTEN
deficiency also causes uncontrolled proliferation and cytokine pro-
duction by both Th1 and Th2 cells, ultimately leading to the
development of lymphoma (Suzuki et al., 2001). Collectively,
PTEN is necessary to keep T cell proliferation in check and
maintain tolerance. We have shown that expression of PHLPP is
crucial for the induction of FOXP3 expression in T cells (Pat-
terson et al., 2011). When PHLPP1 is deleted, conventional T
cells lose the ability to convert into induced Tregs in the pres-
ence of TGF-β. Furthermore, PHLPP expression is up-regulated in
response to TGF-β, consistent with high PHLPP expression found
in natural Treg.
Overall, the differentiation of Th cells into distinct subsets is
clearly modulated by the PI3K pathway. Since these different Th
cell subsets have distinct roles in different immune responses,
modulating the pathway could be used in different therapeutic
approaches. For example, in the case of infectious diseases, it may
be advantageous to enhance PI3K activity and block Tregs and Th2
cells. On the other hand, since inhibitors of p110α, p110γ, AKT, or
mTOR all favor the conversion of conventional T cells into Tregs
(Fruman and Bismuth, 2009; Dutra et al., 2011), these agents have
promise in strategies to induce tolerance.
THE ROLE OF PI3K SIGNALING PATHWAY IN REGULATING T
CELL METABOLISM
Cellular metabolism is a previously under-studied aspect of T cell
biology that has recently gained much attention. As with all cells,
T cells have energy requirements and must generate ATP to sur-
vive and function. In their naive quiescent state, T cells rely on
oxidative metabolism to survive. Upon activation, however, T cells
increase their energy requirements to support proliferation and
effector functions such as cytokine production. Activated effector
T cells must meet this increase of demand for energy and building
blocks for cellular macromolecules by switching to the catabolic
process of glycolysis (Maciver et al., 2008).
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Upon TCR activation in conjunction with CD28 co-
stimulation, T cells increase their ability to uptake glucose by pro-
moting surface trafficking of the glucose transporter GLUT1 and
glycolysis via a process that depends on the PI3K signaling path-
way (Frauwirth et al., 2002; Jacobs et al., 2008). If co-stimulation
is lacking, T cells have a reduced ability to proliferate due to fail-
ure to activate PI3K and increase glycolysis. Furthermore, T cells
with constitutive AKT activation have increased glycolytic activity,
and lose their dependence on CD28 co-stimulation to proliferate
and secrete cytokines. Since ICOS and OX40 co-stimulatory mole-
cules induce strong PI3K activity on activated T cells, it is possible
that their stimulation promotes even stronger glycolytic activity
on antigen experienced T cells. In line with this observation, acti-
vation of co-inhibitory receptors CTLA-4 and PD-1, and the use
of inhibitors of the PI3K pathway, prevents the up-regulation of
glucose uptake in T cells (Frauwirth et al., 2002; Parry et al., 2005;
Wieman et al., 2007). In this section, we will review the differential
cellular metabolic requirements between Treg and conventional T
cells as they relate to the PI3K signaling pathway.
The distinct lineages of CD4+ Th cells differ in their meta-
bolic requirements. Even though Th1, Th2, and Th17 cells all
express GLUT1 and require glycolysis (Michalek et al., 2011), Th17
cells uniquely require a protein known as HIF-1α for their gly-
colytic activity (Shi et al., 2011). Expression of HIF-1α in Th17
cells requires mTOR activation, and thus inhibition of mTOR by
rapamycin blocks HIF-1α induction and expression of glycolytic
enzymes in Th17 cells. HIF-1α is a transcription factor which
responds to changes in oxygen tension and directs cells to switch
from oxidative phosphorylation to aerobic glycolysis (Semenza,
2007). Indeed hypoxia, which activates HIF-1α, promotes skewing
toward Th17 cells and away from Tregs (Dang et al., 2011). Sim-
ilarly, HIF-1α−/− T cells have defective Th17 differentiation, and
are more prone to express FOXP3 and become Tregs. Interestingly,
HIF-1α has been reported to bind and target FOXP3 for ubiquiti-
nation and proteasomal degradation (Dang et al., 2011), providing
a possible mechanism for the observed effects on Tregs. Along with
the role of FOXO on FOXP3 expression and Treg function, these
recent findings on HIF-1α provide an additional mechanism for
how activation of the PI3K pathway can negatively regulate Tregs.
Unlike Th1, Th2, and Th17 cell subsets, Tregs and memory T
cells are relatively quiescent, expressing low amounts of GLUT1
and not requiring high glycolytic activity (Michalek et al., 2011).
Instead of glycolysis, Tregs depend on AMPK, an enzyme which
antagonizes mTOR activation, to perform lipid oxidation and meet
their energetic demands. Metformin, a drug commonly used as to
treat type 2 diabetes, activates AMP, and increases lipid oxidation
and Treg numbers in vivo (Michalek et al., 2011). Since enhanc-
ing Treg numbers in vivo ameliorates insulin resistance in mice
(Feuerer et al., 2009; Winer et al., 2009), further investigation into
whether part of the mechanism of action of metformin in type 2
diabetes is related to enhanced Treg function is warranted.
Since AMPK inhibits Rheb-GTPase mediated mTORC1 acti-
vation (Laplante and Sabatini, 2009), modulating the balance
between mTOR and AMPK can be used to alter T cell metabo-
lism and hence lineage differentiation. For example, rapamycin-
mediated inhibition of mTOR favors AMPK activity and the lipid
oxidation of Tregs (Michalek et al., 2011). Rapamycin can also
reverse the effect of AMPK or LKB1 (upstream kinase for AMPK
activation) deletion, resulting in increased mTORC1 activity, gly-
colysis, and over-production of IFN-γ (Maclver et al., 2011). Since
Tregs and memory T cells are metabolically similar, it is no surprise
that rapamycin can promote the generation of both of these cell
types (Araki et al., 2009; Golovina et al., 2011). Interestingly, TCR
stimulation can activate both mTOR and AMPK (Tamas et al.,
2006), and therefore, the relative strength of the PI3K pathway
activation may be crucial in determining whether a T cell passes
the threshold of mTOR activity to proceed to glycolysis.
Notably, one of the mechanisms that Tregs use to suppress
conventional T cells is through metabolic disruption via CD39,
an ectonucleotidase that hydrolyzes extracellular ATP (Borsellino
et al., 2007). AMPK is preferentially activated in conditions of high
AMP:ATP ratio (Carling et al., 2011). Thus via CD39, Tregs may
be able to promote AMPK activity in their target cells, ultimately
antagonizing mTOR activity. AICAR, a drug that promotes the
activation of AMPK, has been shown to promote T cell anergy
(Zheng et al., 2009), supporting the notion that AMPK activity is
beneficial for immune tolerance.
CONCLUSION
Collectively, the above studies reveal the complexity and intricacies
of signaling requirements for Tregs and different Th cell subsets.
The studies of mice expressing p110δD910A reveal that too little
activity of the PI3K/AKT pathway is detrimental for Tregs. On the
other hand, many studies show that strong PI3K/AKT signaling
activity negatively affects Tregs. These differential effects suggest
that there is likely a certain range of PI3K/AKT signal strength
that is permissive for Tregs. This signal strength is likely deter-
mined by the collective outcome of various extracellular stimuli
that can activate or inhibit PI3K/Akt signaling, thus regulating cel-
lular changes (Figure 2). Because the PI3K/Akt pathway serves as
a critical signaling hub, which directs the balance between inflam-
mation and immune tolerance, it is an ideal target for therapeutic
manipulation.
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